// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

The Introduction of Quanta SC+ to Critical Care for Haemodialysis During the COVID-19 Pandemic

Rechner Ian - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Glomerular Endothelial Glycocalyx Damage Occurs in Human Diabetic Nephropathy and Could Be Prevented by Early Mineralocorticoid Receptor Inhibition

Crompton Michael - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic nephropathy

Spironolactone

Targeting αvβ8 Integrin Improves Renal Function Through Local Inhibition of TGF-β Activation

Liarte Marin Elena - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Integrin aVb8/TGF-b Activation in Kidney Is Associated with Renal Function Deterioration and Can Be Monitored in Urine

Wang Xiaozhen - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Nogo-B and Soluble Nogo-B Modulate VEGFA/VEGFR2 Signalling in Glomerular Endothelial Cells

Ricciardi Carlo Alberto - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Lower Cardiorenal Risk with SGLT2 Inhibitor vs. DPP4 Inhibitor in Type 2 Diabetes Patients Without Established Cardiovascular and Renal Diseases

Birkeland KreI - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Hyperkalaemia Risk and Mortality in Patients with Diabetes

McEwan Philip - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial

Levin Adeera - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Microvascular complications of diabetes 1

Canagliflozin

Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE

L Heerspink HiddoJan - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Canagliflozin

Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

Kang Amy - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Urinary tract infections

Canagliflozin

Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

Kang Amy - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Chronic kidney disease

Canagliflozin

Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analysis from DECLARE-TIMI 58 Trial

Mosenzon Ofri - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dapagliflozin

Renal Outcomes and All-Cause Death Associated with SGLT-2 Inhibitor vs. Other Glucose-Lowering Drugs (CVD-REAL 3 Korea)

Koh Eun Sil - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

N/A

Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist, for Patients with Type 2 Diabetes Mellitus and CKD

Parker VictoriaEr - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Intranasal glucagon

Once-Weekly Exenatide Effects on eGFR Slope and Urine Albumin-to-Creatinine Ratio (UACR) as a Function of Baseline UACR: An EXSCEL Post Hoc Analysis

Clegg Lindsay - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Exenatide

Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs

Cherney David - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal insufficiency

Semaglutide

Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials

Tuttle KatherineR - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Semaglutide

Monocyte-to-Lymphocyte Ratio, an Independent Risk Factor of Survival and Cardiovascular Disease in Hemodialysis Patients: Results from the International MONDO Consortium

Bright RupertBenjamin Graham - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Risk of Hypokalemia in Hyperkalemic Hemodialysis Patients

Fishbane Steven - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predicting Intradialytic Hypotension with Continuous Hemodynamic Monitoring Throughout Hemodialysis

Keane DavidFrancis - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Intradialytic hypotension

N/A

Copyright © 2026. QuantiNova All rights reserved